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ABSTRACT 31 
We report a new approach to the assembly and construction of QconCATs, quantitative concatamers for 32 
proteomic applications that yield stoichiometric quantities of sets of stable isotope-labelled internal standards. 33 
The new approach is based on synthetic biology precepts of biobricks, making use of loop assembly to construct 34 
larger entities from individual biobricks. It offers a major gain in flexibility of QconCAT implementation and enables 35 
rapid and efficient editability that permits, for example, substitution of one peptide for another. The basic building 36 
block (a Qbrick) is a segment of DNA that encodes two or more quantification peptides for a single protein, readily 37 
held in a repository as a library resource. These Qbricks are then assembled in a one tube ligation reaction that 38 
enforces the order of assembly, to yield short QconCATs that are useable for small quantification products. 39 
However, the DNA context of the short also allows a second cycle of assembly such that five different short 40 
QconCATs can be assembled into a longer QconCAT in a second, single tube ligation. From a library of Qbricks, a 41 
bespoke QconCAT can be assembled quickly and efficiently in a form suitable for expression and labelling in vivo 42 





Absolute quantification of proteins by mass spectrometry is typically based on the use of accurately quantified 48 
stable isotope labelled internal standards, usually peptides, as surrogates for the protein quantification. There are 49 
many ways to generate these labelled peptides, including direct chemical synthesis (AQUA peptides, [1, 2] or are 50 
derived from full length labelled proteins (PSAQ, [3–5] or shorter epitopic fragments (PrEST, [6, 7]). An additional 51 
approach is the use of QconCAT technology [4, 8, 9]. QconCATs are multiplexed protein standards for proteomics, 52 
products of artificial genes designed to encode concatamers of peptides, wherein each peptide or more 53 
commonly, a pair of peptides, is chosen to act as mass spectrometric standard(s) for absolute quantification of 54 
multiple peptides. The initial publications on QconCATs [10–12] have received over 1,000 citations and the 55 
methodology is well known and embedded in the community. At a typical size of about 60-70 kDa, a QconCAT 56 
encodes approximately 50 tryptic peptides, permitting the quantification of around 25 proteins at a ratio of two 57 
peptides per protein. The genes are then expressed as recombinant proteins in bacteria grown in the presence of 58 
SIL amino acids, usually lysine and arginine, ensuring a single labelling position for every standard tryptic peptide. 59 
Because the genes are designed de novo, it is feasible to introduce additional features, such as purification tags, 60 
sacrificial peptides to protect the QconCAT from exoproteolysis and peptide sequences, common to each 61 
QconCAT as a quantification standard, permitting absolute quantification of each standard within the proteomics 62 
workflow – in effect, an ‘internally standardised standard’. We have demonstrated that the QconCAT approach 63 
can be used successfully in large scale proteome quantification studies and have reported the absolute 64 
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quantification of approx. 1,800 proteins in the Saccharomyces cerevisiae proteome	 [13], by far the largest 65 
absolute quantification study conducted to date. Because each peptide derived by complete excision from a 66 
QconCAT are present in equal quantities, QconCATs also have utility in determination of subunit stoichiometry of 67 
multiprotein complexes, such as the proteinaceous bacterial metabolosomes for propanediol degradation in 68 
Salmonella	[14]. 69 
 70 
Although QconCATs have been widely adopted, their broader deployment can be challenging. First, QconCAT 71 
expression requires skills in molecular biology and facilities for bacterial expression of heterologous proteins. We 72 
have addressed this in part through the introduction of cell-free synthesis of QconCATs, which brings added 73 
advantages of concurrent, single tube synthesis that we have extended to over 100 QconCATs simultaneously, a 74 
strategy we have dubbed MEERCAT [15, 16]. Secondly, QconCATs cover a set of target proteins based on the 75 
needs of one research group, which may not always match the requirements of subsequent research groups. 76 
Thirdly, the choice of peptides is often obliged to be made without knowledge of the performance of these 77 
peptides in absolute quantification. Lastly, editing of any QconCAT, for example, the removal or addition of a 78 
single protein, has required complete resynthesis and expression of the gene.  79 
 80 
To overcome these complications, we now introduce the concept of ‘ALACATS’ - ‘à la carte’ QconCATs, the term 81 
reflecting the ability to design a QconCAT of any length that encodes peptides for a user-specified set of target 82 
proteins. ALACATS are assembled from ‘Qbricks’, oligonucleotides that encode (typically) two quantotypic 83 
peptides for a single target protein, together with short flanking peptides to recapitulate the correct primary 84 
sequence context, and thus normalise digestion rates. Each Qbrick (one for each target protein in the proteome) 85 
is a discrete entity, a double stranded DNA construct that can be readily synthesised, stored, catalogued and 86 




Design, synthesis and assembly of Qbricks 91 
A Qbrick (‘quantification brick’, a type of biobrick [17]) is defined as a short, double stranded oligonucleotide that 92 
encodes two Qpeptides that are quantotypic for a single protein and is thus the smallest building block (Figure 1). 93 
The Qbrick also encodes interspersed peptide sequences that recapitulate the primary sequence context of the 94 
two peptides, thus equalising digestion rates of standard and analyte. Each Qbrick has asymmetric overhangs at 95 
each end, creating sticky ended DNA molecules that permit assembly by a strategy called ‘Loop Assembly’, driven 96 
by sequential use of two Type IIS restriction endonucleases [18].  Different unique overhang sequences (A, B, C, 97 
D, E and F) flank the Qbricks. Five Qbricks are assembled in a single reaction – the ‘odd’ cycle [18]. The annealing 98 
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during assembly maintains the reading frame through the QconCAT, adding two amino acids to the interspersed 99 
linker with little or no effect on the peptides generated from the QconCAT (Figure 1a). These short QconCATs, 100 
assemblies of five Qbricks that encode 10 peptides, are perfectly useable when expressed as a five-target protein 101 
standard suitable for small, focused studies. A short QconCAT, containing 10 Qpeptides (from five Qbricks), 102 
interspersed linker peptides, quantification and purification peptides as well as suitable sacrificial sequences at 103 
either end, totals approximately 170-220 amino acids, of a size suitable for expression and deployment. 104 
 105 
For more wide-reaching quantification studies, individual short ALACATs are subsequently concatenated in a 106 
second reaction. The initial 5-Qbrick constructs are cloned into plasmids that introduce a second set of six 107 
overhanging linker sequences, distinct from those used in the ‘odd’ cycle. These linkers (‘even cycle’, a, b, g, d, e, 108 
λ; Figure 1b) allow assembly of the five short ALACATs into a complete, ‘long ALACAT’, capable of encoding 109 
Qpeptides for approximately 25 proteins. These QconCATs would be 75-90 kDa (relatively shorter because of the 110 
single instances of N-terminal and C-terminal features), typical for cell-free or bacterial expression. Of course, any 111 
variant, from two to five short ALACATs, encoding quantification standards for any number of proteins between 112 
5 and approximately 30 is possible using this approach. This greatly expands the flexibility of the QconCAT 113 
approach. The sequences of the constructs used in this paper, and the cloning syntaxes, are provided in 114 
Supplementary Sequence File A. 115 
 116 
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Figure 1| Overall strategy for building block assembly of short and long ALACATs 
The smallest unit of an ALACAT is a single double stranded oligonucleotide encoding peptides (one, two, more) 
for quantification of a single target protein, flanked on either side by tripeptides that preserve the natural 
primary sequence context. These oligonucleotides include linker regions compatible with a Type IIS restriction 
enzyme (BsaI) that allows all five Qbricks to be assembled in the correct order in a single ligation reaction (panel 
a, odd cycle assembly) to form short ALACATs. In turn, these short ALACATs contain DNA sequences that are 
compatible with a second Type IIS restriction enzyme (SapI) and can be similarly assembled in a one tube 
reaction to create a long ALACAT (panel b, even cycle assembly). The vectors for the odd and even cycles both 




As proof of concept, we built an ALACAT from a series of Qbricks encoding standards for 25 human plasma 118 





















a) Odd cycle to create short ALACATs
b) Even cycle to create full length, long ALACATs
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a long ALACAT. Each short ALACAT was expressed independently in a wheat germ cell free system (CFS), as well 120 
as the long ALACAT and yields of all were high (Figure 2a). Typically, yields were of the order of 500 pmol, which 121 
is a substantial quantity for LC-MS/MS based quantification (typically, a single LC-MSMS run would require 50 122 
fmol on column). The expressed short and long QconCATs were then digested with trypsin and analysed by LC-123 




Figure 2 | Construction of a human plasma protein QconCAT using the ALACAT strategy 
A series of Qbricks were designed, each encoding two peptides for each of 25 plasma proteins. Groups 
of five were assembled in an odd cycle reaction to short ALACATs (301-305) that were expressed in vitro 
using wheat germ lysate and purified by virtue of their hexahistidine tag. In addition, the short ALACATs 
were assembled in an even cycle reaction into a single long ALACAT that was also expressed and purified 
(panel a). Each of the ALACATs were then digested and analysed by LC-MSMS; all peptides were 
detected (panel c, infilled peptides are those visible by LC-MS/MS (panel b); different colours define the 
short ALACAT origins of the peptides in the long ALACAT). Using common peptides (glu fibrinopeptide 
and c-myc epitope) as normalisation controls, the peak areas for peptides in short ALACATs were 
compared to the areas of the same peptides in the long ALACATs (panel d) 
 
 127 
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Each QconCAT contained two common peptides - the glu fibrinopeptide (EGVNDNEEGFFSAR) that we have used 128 
previously for quantification of the QconCAT [8, 13] and a second peptide derived from the common c-myc 129 
peptide (LISEEDLGGR) to give a tag for monitoring expression by western blotting if necessary. We were able to 130 
use these two peptides to assess the consistency of the intensity of the quantification peptide, whether in long 131 
or short ALACATs (Figure 2c). The correlation was extremely high, confirming that the peptides were cleaved and 132 
released similarly, irrespective of the nature of the ALACAT. 133 
 134 
We also demonstrated the synthesis of ALACAT in a E. coli cell-free system. The E. coli system couples transcription 135 
and translation in a single tube, which allows us to skip the in vitro transcription reaction required in the wheat 136 
cell-free system. In this study, we set up a small-scale reaction system using a microdialysis device (Figure 3). All 137 
prepared ALACAT genes were successfully synthesized in this system), and the efficiency of 13C/15N incorporation 138 
into their lysine and arginine residues was more than 99 %. 139 
 140 
 
Figure 3. ALACAT synthesis by E. coli cell-free system 
Experimental design for cell-free synthesis (panel a). Ten small ALACATs (belonging to two series; ‘B’ and ‘H’) and one 
long ALACAT were synthesized in a small-scale cell-free synthesis system using a microdialysis device (panel b). Lysine 
and arginine residues of the synthesized ALACATs were labelled with 13C/15N. Panel b) Representative SDS-PAGE 
separation images of the synthesized ALACATs. His-tag purified ALACATs were separated by NuPAGE 4–12 % gradient 
gels and visualized by CBB staining. Asterisk: ALACAT band. Panel c) Selective reaction monitoring (SRM) analysis of 
ALACAT peptides. The efficiency of stable isotope incorporation was estimated by SRM for two tryptic digested 
peptides derived from one ALACAT. 
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Editability of ALACATs 141 
One of the advantages of the ALACAT approach is the introduction of straightforward editability of the construct. 142 
Previously, there was no simple route to exchange one peptide for another without extensive resynthesis of the 143 
gene. However, with ALACATs, the editability simplifies the introduction of changes in the sequence and 144 
embedded peptides. This editing process can take place at two levels. First, individual peptides can be replaced 145 
in Qbricks, and a new short ALACAT could be constructed. The only new DNA required would be the sequence of 146 
the Qbrick. Alternatively, an entire short ALACAT could be exchanged, replacing multiple peptides in a single 147 
process. This might be of particular value, for example, in a multi-species construct, if some short ALACATs 148 
contained species-specific peptide sequences, and others contained sequences that were identical in both 149 
species. A simple switch from species A to species B would only require exchange of the relevant short ALACAT in 150 
the one-step, even cycle ligation reaction.  Further, about 10% of all traditionally synthesised QconCATs failed to 151 
express in bacteria [16] and the ability to quickly create a large set of rearrangements of different Qbricks or short 152 
ALACATs would be able to deliver a library of ALACATs, with equivalent function, that could be quickly screened 153 
for expression potential. Alternatively, this type of combinatorial synthesis could be used to explore adjacency 154 
and proximity effects. To test this possibility in extremis we therefore initiated a ‘one pot’ combinatorial ligation 155 
of two families of Qbricks, or two families of short ALACATs. 156 
 157 
We tested both levels of editability using the two ALACAT series (B, plasma and H for analysis of the stoichiometry 158 
of a metabolic compartment; Supplementary Sequence File A) described above. First, we demonstrated the ease 159 
of exchange of short ALACATs by building a combinatorial series of long ALACATs created from random 160 
introduction of appropriate short ALACATs – the ‘even’ cycle. Each position in the long ALACAT could contain a 161 
short ALACAT from either the B or H series. Rather than create one editing reaction to prove the swap of one 162 
short ALACAT for another, we took a different approach and set up a single reaction, in which we mixed ten short 163 
ALACATs derived from the two different families, prefixed B and H, such that B1 and H1 would share common 164 
SapI overhang sequences and similarly, the other four pairs (H2/B2 to H5/B5). Thus, short ALACATs H1 and B1 165 
would represent a binary choice at position one. In this assembly, a random ligation process would generate 25 = 166 
32 different combinations, from H1:H2:H3:H4:H5 through, for example, H1:H2:B3:B4:B5 etc. to B1:B2:B3:B4:B5. 167 
After the single tube ligation, 81 colonies were picked and the ligation product DNA was sequenced. Of the 32 168 
combinations that could have been synthesised, we detected 26 different short ALACATs (80% of all possible 169 
different combinations, Figure 4, Supplementary Sequence File B), confirming the ease of editing and 170 
reconstruction of new short ALACATs. There was no indication of any systematic bias in the selection of one or 171 
the other sets of Qbricks, establishing the ease of random ligation. 172 
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Figure 4| Combinatorial assembly of short ALACATs into long ALACATs 
To test the ease of editability and swapping of short ALACATs into long ALACATs, we created a ligation reaction in 
which there were two choices of short ALACAT at each of four or five positions (panel a). The reaction products 
were cloned and a total of 81 clones were selected for DNA sequencing, to establish the composition of the long 
ALACATs (from either the B or H series) were incorporated (panel b). There was an even representation of the short 
ALACATs across the entire structure (panel c) and the evenness of the creation of the products is evidenced by the 
split of the products through the first three positions (panel d). 
 
a) Combinatorial ligation of short ALACATs
b) Colony picking, DNA sequencing
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To assess the equivalent combinatorial substitution of Qbricks, we performed essentially the same experiment in 173 
an ‘even’ cycle but with two set of Qbricks from the two families (B and H), again picking multiple clones from a 174 
single tube ligation reaction. To increase complexity, we created further potential by providing H4 and B5 with 175 
two assembly contexts (Figure 5, Supplementary Sequence File C). After assembly, multiple ALACAT clones were 176 
picked and sequenced. From this experiment, 26 unique short ALACATs were constructed, spread across 65 177 
sequences that were sampled.  Of these 65, seven were long variants of five Qbricks (made possible by our 178 
construction strategy) but the majority comprised assemblies of four Qbricks, a total of 19 combinations from a 179 
set of 24 possibilities were recovered. Further, 16 were unique, two were replicated once, three occurred thrice, 180 
two were four-fold, up to one assembly that was sequenced in 16 (approx. 25%) of the clones. It is possible that 181 
this bias reflected differences in the relative concentrations of the input DNA sequences, which would allow for 182 
the possibility of a degree of tuning of the system to preferred assemblies. 183 
 184 
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Figure 5| Combinatorial assembly of Qbricks into short ALACATs 
To test the ease of editability and swapping of Qbricks into short ALACATs, we created a ligation reaction in which there were two 
choices of Qbrick at each of four or five positions (panel a), encoding pairs of quantotypic peptides P1 and P2. The reaction products 
were cloned and a total of 65 clones were selected for DNA sequencing, to establish the composition of the long ALACATs (from either 
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Discussion 186 
The Qbrick concept has multiple advantages over traditional QconCAT gene synthesis and expression. First, the 187 
individual Qbrick DNA oligonucleotides can be drawn from an ever-expanding library, stored at the point of 188 
synthesis, and thus, the clustering of Qpeptides into QconCATs becomes a late decision, driven by the interests 189 
of specific users and programmes. Secondly, ALACATs can be designed and delivered at any size, according to the 190 
focus and depth of individual quantitative proteomics studies. For example, two or three short ALACATs can be 191 
combined to form highly efficient QconCATs of intermediate size. Lastly, if specific peptides are suboptimal for a 192 
particular mass spectrometric approach, often an unknown factor before the construct is made, it is trivial to 193 
replace one Qbrick, build a new short ALACAT, and if required, subsequently assemble the new short ALACAT into 194 
the full length ALACAT, both steps being single-tube reactions. This is an exciting improvement in QconCAT 195 
deployment, providing an efficiency and flexibility which, coupled with cell-free synthesis and MEERCAT, means 196 
that large scale absolute proteome quantifications are now eminently feasible, sustainable and modifiable. 197 
Moreover, many stages of the ALACAT workflow are suitable for delivery through laboratory automation, reducing 198 
the need for human intervention. The Qbrick approach means that it would be possible to create an ever-199 
expanding resource of Qbrick DNA (in the form of double stranded oligonucleotides) that could be assembled ‘to 200 
order’ in response to requests by any research group. There would be no reliance on prior clustering of peptides, 201 
and the assembly would be a trivial additional step. Moreover, the ability to ‘swap out’ specific Qbricks without 202 
having to redesign and build the QconCAT from scratch means that problematic peptides will be rapidly expunged 203 
from the resource (Figure 6). The advantages of having ‘editable QconCATs’ cannot be overstated. This added 204 
flexibility in standard design and optimisation, coupled with ever increasing selectivity and sensitivity of LC-MS/MS 205 
platforms, makes absolute quantification of part, or even all, of a proteome increasingly feasible. 206 
 207 
Lastly, QconCATs, assemblies of peptides generated by proteolysis, are a simple route to the generation of 208 
stoichiometric quantities of a set of peptides that can be used for purposes other than absolute quantification, 209 
such as instrument quality control or calibration of retention time index ([19–23]).The combinatorial experiments 210 
described in this paper, for example, create the ability to build a large number of different combinations of 211 
peptides from a common library, and could be used in the understanding of local influences on ionisation, or even 212 
to test the emergent methods for prediction of precursor or product ion intensity [24–29]. The more 213 
straightforward the production methodology, the more likely tests of such predictive methods can be created. 214 
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Figure 6| A model for the creation of an ALACAT resource 
From a library of Qbricks (that may include redundant sequences to increase the choice of quantotypic peptides for specific proteins) 
assembly into short ALACATs would provide a test system to assess the suitability of peptides for quantification. Once the short ALACATs 
are optimised, sets of them could subsequently be assembled into long ALACATs. Long ALACAT DNA can be readily used to drive protein 
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EXPERIMENTAL 226 
Materials and reagents. All enzymes, competent cells and manual DNA purification kits were purchased from 227 
New England Biolabs (Hitchin, UK), all oligonucleotides were purchased desalted and lyophilised from 228 
Integrated DNA Technologies BVBA (Leuven, Belgium) or Eurofins Genomics (Ebersberg, Germany). All 229 
bacterial media and antibiotics were purchased from Formedium Ltd (Hunstanton, UK).  230 
 231 
Production of pOdd and pEven acceptor vectors. Plasmid pEU01-MCS (CellFree Sciences, Ehime, Japan) was 232 
domesticated via site-directed mutagenesis to remove unwanted BsaI and SapI restriction sites. pOdd 233 
vectors were produced by inserting a lacZ cassette with SapI and BsaI sites as indicated with appropriate 234 
syntaxes flanked N-terminally by GluFib and Myc tag linkers and C-terminally with 6x His-Tag and stop 235 
codons. pEven vectors were produced similarly but the AmpR gene was exchanged for SpecR gene amplified 236 
from pGM134_1 and cloned via an NEBuilder (NEB, UK) reaction. All lacZ cassettes were synthesised by Twist 237 
Bioscience (San Francisco, USA) and cloned as single fragments into modified pEU01-MCS via NEBuilder, 238 
producing pOdd vectors pGM247_2 – 6 and pEven vectors pGM247_8 – 12.  239 
 240 
Design of oligonucleotides and production of QBrick DNA Blocks. QBrick peptide sequences were reverse 241 
translated using Geneious software (Biomatters Ltd), set up to use the Escherichia coli K12 codon usage table 242 
[30] and to avoid internal restriction sites of BsaI, SapI, BbsI and BsmBI and >5 nt homopolymers. These were 243 
converted to overlapping oligonucleotides (Tann approx. 60°C). Required 5' overhangs for BsaI or SapI 244 
recognition sequences and molecular syntaxes were then added. Pairs of overlapping oligonucleotides were 245 
mixed at 2.5 µM ea. (final conc.) in Q5 2x mastermix in 20 µl total reaction. These were annealed and 246 
extended using the following thermocycler parameters: 98°C for 60 s followed by five cycles of 98°C for 10 247 
s, 60°C for 30 s, 72°C for 15 s and a final incubation at 72°C for 60 s. These reactions were diluted 1:100 in 248 
water before added to cloning reactions below (approx. 25 fmol/µl).  249 
 250 
Odd level cloning reactions (Short ALACATs). Required QBrick blocks (~25 fmol·µL-1) were reacted with empty 251 
pOdd vector in 10 µL total as follows: 0.5 µL each QBrick block, 10 ng pOdd vector, 1 µL T4 DNA Ligase Buffer, 252 
0.5 µL T4 DNA Ligase (400 U·µL-1), 0.5 µL BsaI (10 U·µL-1). These were incubated with the following conditions: 253 
37°C for 10 min, followed by 50 cycles of 37°C for 1 min and 16°C for 1.5 min before final 50°C for 5 min. 1 254 
µL of the reaction was transformed into 25 µL of NEB 5-alpha chemically competent cells. 20% were plated 255 
onto LB agar plates containing 100 µg·mL-1 Carbenicillin, 20 µg·mL-1 X-Gal and 100 µM IPTG for blue/white 256 
selection. White colonies were then screened by colony PCR using universal screening primers (Forward: 5'-257 
TAACCACCTATCTACATCACC-3' and Reverse: 5'-CGAGCTCGAGAACTAGTGAT-3'). PCR products were analysed 258 
using QIAxcel DNA Screening Gel automated electrophoresis (QIAGEN, Manchester, UK). Correct PCR 259 
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products were cleaned with ExoCIP and Sanger sequenced (Source Bioscience Ltd, Nottingham, UK) to 260 
confirm the sequence.  261 
  262 
Even level cloning reactions (Long ALACATs). Required pOdd clones (10 ng·µL-1) were reacted with empty 263 
pEven vector in 10 µL total as follows: 0.5 µL each pOdd clone, 10 ng pEven vector, 1 µL 10x T4 Ligase Buffer, 264 
0.5 µL T4 DNA Ligase (400 U·µL-1), 0.5 µL SapI (10 U·µL-1). These were incubated at 37°C for 120 min. 1 µL of 265 
the reaction was transformed into 25 µL of NEB 5-alpha chemically competent cells. 20% were plated onto 266 
LB agar plates containing 50 µg·mL-1 Spectinomycin, 20 µg·mL-1 X-Gal and 100 µM IPTG. White colonies were 267 
then screened by colony PCR using universal screening primers (Forward: 5'-TAACCACCTATCTACATCACC-3' 268 
and Reverse: 5'-CGAGCTCGAGAACTAGTGAT-3'). PCR products were analysed using QIAxcel DNA Screening 269 
Gel electrophoresis. 270 
 271 
Cell-free expression of short and long ALACATs. For each ALACAT, 2 μg DNA in pEU-E01 vector (CellFree 272 
Sciences Co., Ltd, Japan) was used for a single expression reaction. Synthesis was completed in 240 μL scale 273 
using WEPR8240H full Expression kit (2BScientific Ltd, UK). A positive control (pEU-E01-DHFR coding 274 
dihydrofolate reductase gene derived from E. coli) and negative control (pEU-E01-MCS empty vector) were 275 
used, both supplied with the kit. Full kit instructions were followed, including preparation of WEPRO8240H 276 
aliquots and 2 x SUB AMIX reagent. The Transcription Mix for each expression was prepared with 20 U RNase 277 
inhibitor, 20 U SP6 RNA Polymerase, 50 nmol NTP mix and a 0.2 x dilution Transcription Buffer. DNA for the 278 
ALACAT or controls, and nuclease-free water, were added to a final volume of 20 μL. The transcription 279 
reaction occurred over six hours at 37 °C and the resulting mRNA was stored briefly at room temperature 280 
before transcription.  281 
 282 
A 1 x SUB AMIX was prepared with a 0.5 x dilution of 2 x SUB AMIX into nuclease-free water and 60 nmol of 283 
each of the standard 20 amino acids (R, K, A, N, D, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V), with substituted 284 
stable isotope labelled [13C6],[15N4] arginine and [13C6],[15N2] lysine (CK Isotopes Ltd, UK). The Translation Mix 285 
for each expression was prepared with 12 nmol of each of the same standard 20 amino acids, including 13C6 286 
15N Arg and Lys, combined with 0.8 μg creatinine kinase, 10 μL WEPRO8240H wheat germ lysate, 0.5 x 287 
dilution of 2 x SUB AMIX, and 10 μL of mRNA for each ALACAT or standard. A 96-well plate was prepared with 288 
200 μL of 1 x SUB AMIX in each well. The Translation Mixture was carefully pipetted beneath the SUB AMIX 289 
in each well to form a bilayer. The plate was sealed and incubated at 16 °C for 16 hours.  290 
 291 
E. coli cell-free synthesis was performed using a Musaibou-Kun protein synthesis kit (Catalog #A183-0242, 292 
Taiyo Nippon Sanso Corporation, Tokyo, Japan). For ALACAT synthesis, an amino acid cocktail with lysine and 293 
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arginine universally labeled with 13C and 15N (Catalog # A91-0128, Taiyo Nippon Sanso Corporation) was used. 294 
All synthetic reactions were performed using an Xpress micro-dialyzer MD100 with molecular weight cut-off 295 
of 12–14 kDa (Scienova, Spitzweidenweg, Germany) inserted into a 2 mL microtube. Before synthesis, 825 296 
μL of the outer solution was mixed with 75 μL amino acid cocktail and 100 μL distilled water, incubated at 30 297 
°C, and added to the outside of the dialysis unit at the start of synthesis. Then, 77.5 μL of the internal solution 298 
for synthesis was mixed with 10 μL template DNA (50 ng/μL), 7.5 μL amino acid cocktail, and 5 μL distilled 299 
water, and added to the dialysis unit. The synthesis reaction was carried out at 30 °C for 18 hours. After the 300 
synthesis was completed, all the solution in the dialysis unit was collected into a new tube. 301 
 302 
ALACAT purification. Note that the positive control used for expression does not have a hexa-histidine tag 303 
and therefore both controls were used as negative controls in this next stage of the protocol. The 240 μL 304 
contents of each individual well of the 96 well plate was transferred to a low binding tube (Biotix Inc., US). 305 
This was then combined with 400 μL Bind Buffer pH 7.4 (20 mM sodium phosphate, 0.5 M sodium chloride, 306 
20 mM imidazole, 6 M guanidine hydrochloride), and incubated at room temperature for one hour using a 307 
rotor mixer, before addition of 10 μL Ni Sepharose suspension (GE Healthcare Ltd, UK) and a further one 308 
hour incubation. Centrifuge filters (Corning Costar Spin-X 0.45 um pore size cellulose acetate membrane, 309 
Merck, UK) were washed once with 750 μL Bind Buffer and centrifuged, before addition of the sample and 310 
Ni Sepharose, and further centrifugation; all centrifuge steps used 6,000 x g 2 minutes 4 °C. This was followed 311 
by three further washes by centrifugation with Bind Buffer; two 400 μL washes and one 200 μL wash. Sample 312 
was eluted by centrifugation from the resin with two additions of 15 μL Elution Buffer pH 7.4 (20 mM sodium 313 
phosphate, 0.5 M sodium chloride, 1 M imidazole, 6 M guanidine hydrochloride), after each addition the 314 
resin and buffer were agitated to mix before centrifugation.  315 
 316 
The final 30 μL elution was transferred to a low binding tube for protein precipitation. To each tube 600 μL 317 
HPLC grade methanol (Fisher Scientific Ltd, UK) was added and mixed well before addition of 150 μL 318 
chloroform and 400 μL HPLC grade water (VWR International, UK) to precipitate proteins. Following 319 
centrifugation at 13,000 x g for 3 minutes a bilayer was formed, the uppermost layer of which was carefully 320 
removed. A further 600 μL methanol was added and gently mixed by inversion. After a second centrifugation 321 
step the majority of the liquid was removed and discarded, with the remaining liquid allowed to evaporate. 322 
The precipitate was resuspended in 30 μL 25 mM ammonium bicarbonate, with 0.1 % (w/v) RapiGestTM SF 323 
surfactant (Waters, UK) and protease inhibitors (Roche cOmpleteTM, Mini, EDTA-free Protease Inhibitor 324 
Cocktail, Merck, UK).  Before tryptic digestions the protein concentration of each sample was determined 325 
using a NanoDrop Spectrophotometer (ThermoFisher Scientific, UK).  326 
 327 
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Tryptic digestion. For digestion, 0.5 μg protein for each was treated with 0.05 % (w/v) RapiGestTM SF 328 
surfactant at 80 °C for 10 minutes, reduced with 4 mM dithiothreitol (Melford Laboratories Ltd., UK) at 60 °C 329 
for 10 minutes and subsequently alkylated with 14 mM iodoacetamide at room temperature for 30 minutes. 330 
Proteins were digested with 0.01 μg Trypsin Gold, Mass Spectrometry Grade (Promega, US) at 37 °C 331 
overnight. Digests were acidified by addition of trifluoroacetic acid (Greyhound Chromatography and Allied 332 
Chemicals, UK) to a final concentration of 0.5 % (v/v) and incubated at 37 °C for 45 minutes before 333 
centrifugation at 13,000 x g 4°C to remove insoluble non-peptidic material.  334 
 335 
LC-MS/MS. Samples were analysed using an UltiMateTM 3000 RSLCnano system coupled to a Q Exactive™ HF 336 
Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (ThermoFisher Scientific, UK). Protein digests were loaded 337 
onto a trapping column (Acclaim PepMap 100 C18, 75 µm x 2 cm, 3 µm packing material, 100 Å) using 0.1 % 338 
(v/v) trifluoroacetic acid, 2 % (v/v) acetonitrile in water at a flow rate of 12 µL min-1 for 7 min. For samples 339 
301, 302 and 304, 5 ng was loaded, and for the Long ALACAT, 303 and 305, 10ng was loaded. The peptides 340 
were eluted onto the analytical column (EASY-Spray PepMap RSLC C18, 75 µm x 50 cm, 2 µm packing 341 
material, 100 Å) at 30 °C using a linear gradient of 30 minutes rising from 3 % (v/v) acetonitrile/0.1 % (v/v) 342 
formic acid (Fisher Scientific, UK) to 40 % (v/v) acetonitrile/0.1 % (v/v) formic acid at a flow rate of 300 nL 343 
min-1. The column was then washed with 79 % (v/v) acetonitrile/0.1 % (v/v) formic acid for 5 min, and re-344 
equilibrated to starting conditions. The nano-liquid chromatograph was operated under the control of Dionex 345 
Chromatography MS Link 2.14. 346 
 347 
The nano-electrospray ionisation source was operated in positive polarity under the control of QExactive HF 348 
Tune (version 2.5.0.2042), with a spray voltage of 1.8 kV and a capillary temperature of 250 °C.  The mass 349 
spectrometer was operated in data-dependent acquisition mode.  Full MS survey scans between m/z 350-350 
2000 were acquired at a mass resolution of 60,000 (full width at half maximum at m/z 200).  For MS, the 351 
automatic gain control target was set to 3e6, and the maximum injection time was 100 ms.  The 16 most 352 
intense precursor ions with charge states of 2-5 were selected for MS/MS with an isolation window of 2 m/z 353 
units.  Product ion spectra were recorded between m/z 200-2000 at a mass resolution of 30,000 (full width 354 
at half maximum at m/z 200). For MS/MS, the automatic gain control target was set to 1e5, and the maximum 355 
injection time was 45 ms. Higher-energy collisional dissociation was performed to fragment the selected 356 
precursor ions using a normalised collision energy of 30 %. Dynamic exclusion was set to 30 s. 357 
 358 
The raw MS data files were loaded into Thermo Proteome Discoverer v.1.4 (ThermoFisher Scientific, UK) and 359 
searched against a custom ALACATs database using Mascot v.2.7 (Matrix Science London, UK) with trypsin 360 
as the specified enzyme, one missed cleavage allowed, carbamidomethylation of cysteine, label 361 
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[13C6][15N2]lysine and [13C6][15N4]arginine set as fixed modifications and oxidation of methionine set as a 362 
variable modification. A precursor mass tolerance of 10 ppm and a fragment ion mass tolerance of 0.01 Da 363 
were applied.  364 
	365 
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